Tuftsin augments antitumor efficacy of liposomized etoposide against fibrosarcoma in Swiss albino mice

Molecular Medicine

Volumn 13, Issue 5-6, 2007, Pages 266-276

  Khan, Arif ^a   Khan, Aijaz A ^b   Dwivedi, Varun ^b   Ahmad, Manzoor G ^b   Hakeem, Seema ^b   Owais, Mohammad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; LIPOSOME; PROTEIN P53; PROTEIN P53MUT; PROTEIN P53WT; TUFTSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FIBROSARCOMA; HISTOPATHOLOGY; IMMUNOMODULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD CELL COUNT; BODY WEIGHT; BUFFERS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; FIBROSARCOMA; LIPOSOMES; MICE; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME; TUFTSIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34547400441     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2007-00018.Khan     Document Type: Article

References (69)

1. Hande KR. (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 34:1514-21.
2. Spurgers KB, Gold DL, Coombes KR, et al. (2006) Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J. Biol. Chem. 281(35):25134-42.
3. Natalie OK, Tafani M, Rothman RJ, Russo MA, Farber JL. (2002) The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J. Biol. Chem. 277:16547-52.
4. Huang Y, Chan AML, Liu Y, Wang X, Holbrook NJ. (1997) Serum withdrawal and etoposide induce apoptosis in human lung carcinoma cell line A549 via distinct pathways. Apoptosis 2:199-206.
5. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE. (1989) A phase II study of oral etoposide in elderly patients with small cell lung cancer. Thorax 44:631-3.
6. Dollery C. (1999). Etoposide. In: Dollery C, ed. Therapeutic Drugs. London, UK: Churchill Livingstone E103- E108.
7. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316:1435-40.
8. Sinkule JA. (1984) Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 4:61-73.
9. Postmus PE, Mulder NH, Sleijfer DT, Meinesz AF, Vriesendorp R, de Vries EG. (1984) High-dose etoposide for refractory malignancies: A phase I study. Cancer Treat. Rep. 68:1471-4.
10. Hande KR. (1994) Etoposide pharmacology. Semin. Oncol. 19(13):3-9.
11. O'Dwyer PJ, Weiss RB. (1984). Hypersensitivity reactions induced by etoposide. Cancer Treat. Rep. 68:959-61.
12. Marina NM, Cochrane D, Harney E, et al. (2002) Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (doxil) in children with solid tumors: a pediatric oncology group study. Clin. Cancer Res. 8:413-8.
13. Batist G, Ramakrishnan G, Rao CS, et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19:1444-54.
14. Chidiac T, Budd GT, Pelley R, et al. (2000) Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Investig. New Drugs 18:253-9.
15. Gabizon A, Martin F. (1997) Polyethylene glycolcoated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs 54:15-21.
16. Gabizon A. (1992). Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:891-6.
17. Vaage J, Mayhew E, Lasic D, Martin F. (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer 5:942-8.
18. Tyagi P, Sengupta S, Velpandian T, Gupta YK, Kochupillai V, Gupta SK. (1999) Evaluations of the antitumour activity of liposomal formulations of etoposide against choriocarcinoma xenograft in Balb/c nu/nu mice. Pharm. Pharmacol. Commun. 5:595-8.
19. Sengupta S, Velpandian T, Sapra P, Sanyal M, Gupta SK. (1998) Etoposide encapsulated long circulating liposomes; improved antitumour efficacy with reduced adverse effects. Naunyn Schmeideberg's Arch. Pharmacol. 358:R531.
20. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK: (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:3352-6.
21. Papahadjopoulos D, Allen TM, Gabizon A, et al. (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S. A. 88:11460-4.
22. Nishioka K, Amoscato AA, Babcock GF. (1981) Tuftsin: a hormone-like tetrapeptide with antimicrobial and antitumor activities. Life Sci. 28:1081-90.
23. Nishioka K, Babcock GF, Phillips JH, Banks RA, Amoscato AA.(1983) In vivo and in vitro antitumor activities of tuftsin. Ann. N. Y. Acad. Sci. 419:234-41.
24. Sengupta S, Tyagi P, Chandra S, Kochupillai V, Gupta SK. (2001) Encapsulation in cationic liposomes enhances antitumour efficacy and reduces the toxicity of etoposide, a topoisomerase II inhibitor. Pharmacology 62:163-71.
25. Owais M, Krishnakumar B, Jain RK, Bachhawat BK, Gupta CM. (1993) Tuftsin bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett. 326:56-8.
26. Gupta CM, Puri A, Jain RK, Bali A, Anand N. (1986) Protection of mice against P. berghei infection by a tuftsin derivative. FEBS Lett. 205:351-4.
27. Khan MA, Faisal SM, Haque W, Owais M (2002). Immunomodulator tuftsin augments antifungal activity of amphotericion B against experimental murine candidiasis. J. Drug Target 10(3):185-92.
28. Owais M, Gupta CM. (2000) Liposome mediated cytosolic delivery of macromolecules and its possible use in vaccine development. Eur. J. Biochem. 267:3946-56.
29. Faiderbe S, Chagnaud JL, Geffard M. (1992) Identification and characterization of a specific autoantiphosphatidylinositol immune response during the time course of benzo (a) pyrene-induced malignant tumors in female Sprague-Dawley rats. Cancer Res. 1992;52:2862-5.
30. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr. (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 44:717-26.
31. Serpi R, Piispala J, Jarvilehto M, Vahakangas K. (1999) Thapsigargin has similar effect on p53 protein response to benzo (a) pyrene DNA adducts as TPA in mouse skin. Carcinogenesis 20:1755-60.
32. Towbin H, Staehelin T, Gordon J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A. 76:4350-4.
33. Lowry OH, Rosenbrough NK, Farr AL, Randall RJ. (1951) Protein measurement with folin phenol reagent. J Biol Chem 193:265-75.
34. Borst P, Evers R, Kool M, Wijnholds J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Nat. Cancer Inst. 92(16):1295-302.
35. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem. 276(49):46400-7.
36. Guo A, Marinaro W, Hu P, Sinko PJ. (2002) Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Dispos. 30(4):457-63.
37. Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R. (2006) Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukemia despite expression of multidrug resistance related proteins. Eur. J. Haematol. 77:293-9.
38. Sadava D, Coleman A, Kane SE. (2002) Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells. J. Liposome Res. 12:301-9.
39. Lo YL, Liu FI, Yang JM, Cherng JY. (2001) Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. Anticancer Res. 21:445-50.
40. Lawrence DM and Jennifer AS. (2001) The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev. 20:87-93.
41. Poujol S, Tilleul P, Astre C, Martel P, Fabbro M, Pinquet F. (1999) Effect of mitoxantrone liposomes on multidrug-resistant breast cancer cells. Anticancer Res. 19:3327-31.
42. Knyszynski A, Gottilieb B, Fridkin M. (1983) Inhibition by tuftsin of Rauscher virus leukemia development in mice. J. Nat. Cancer Inst. 71:87-90.
43. Noyes RD, Babcock GF, Nishioka K. (1981) Antitumor activity of tuftsin on murine melanoma in vivo. Cancer Treat. Rep. 65:673-5.
44. Bugelski PJ, Cotwon SP, North SM, Kirsh R, Nicolson GM, Poste G. (1987) Macrophage content of spontaneous metastases at different stages of growth. Cancer Res. 47: 4141-7.
45. Bugelski PJ, Kirsh R, Ruscarmo C, Cotwin SP, Poste G. (1987) Recruitment of exogeneous macrophages into metastases at different stages of tumor growth. Cancer Immunol. Immunother. 24:93-8.
46. Evans R, Cullen RT. (1984) In situ proliferation of intra tumor macrophages. J. Leuk. Biol. 35:561-8.
47. Normann SJ. (1985) Macrophage infiltration and tumor progression. Cancer Metastasis Rev. 4:277-91.
48. Mantovani A. (1990) Tumor-associated macrophages. Curr. Opin. Immunol. 2:689-94.
49. Fidler IJ, Schroit AJ. (1988) Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim. Biophys. Acta. 948:151-73.
50. Killion JJ, Radinsky RR, Dong Z, Fishbeck R, Whitworth P, Fidler IJ. (1993) The immunogenic properties of drug resistant murine tumor cells do not correlate with expression of the MDR phenotype. Cancer Immunol. Immunother. 36:381-6.
51. Pak CC, Fidler IJ. (1989) Activated macrophages distinguish undifferentiated-tumorigenic from differentiated-nontumorgenic murine erythroleukemia cells. Differentiation 41:49-55.
52. Fidler IJ. (1986) Optimization and limitations of systemic treatment of murine melanoma metastasis with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother. 21:169-73.
53. Deodhar SD, James K, Chiang T, Barna BP. (1982) Inhibition of lung metastasis in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res. 42:5084-91.
54. Eppstein DA, Vander Pas MA, Fraser-Smith EB. (1986) Liposome-encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int. J. Immunother. 1986;2:115-26.
55. Lopez-Berestein G, Milas L, Hunter N, Mehta E, Eppstein D, Vander Pas MA, Mathews TR, Hersh EM. (1984) Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-0-steroyl-N-acetylmuramyl-L-amino-butryl-D-isoglutamine. Clin. Exp. Metastasis 2:366-7.
56. Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard TM. (1985) Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 39:2582-90.
57. Phillips NC, Tsao MS. (1989) Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res. 49:936-9.
58. Brodt P, Blore J, Philips NC, Munzer JS, Rioux JD.(1989) Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide. Cancer Immunol. Immunother. 28:54-60.
59. Thrombe P, Deodhar SD. (1984) Inhibition of liver metastasis in murine colon adenocarcinoma by liposomes containing human C-reactive protein or crude lymphokine. Cancer Immunol. Immunother. 16:145-50.
60. Khan MA, Arif K, Owais M. (2005) Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice. FEMS Immunol. Med. Microbiol. 46(1):63-9.
61. Khan MA, Nasti TH, Khanam S, et al. (2004) Coadministration of immunomodulator tuftsin and liposomised-nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. FEMS Immunol. Med. Microbiol. 41:249-58.
62. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. (1998) The p53 network. J. Biol. Chem. 273:1-4.
63. Mowat MR. (1993) p53 in tumor progression: life, death and everything. Adv. Cancer Res. 74:25-48.
64. Hollstein M, Sidransky D, Vogelstein B, Harris CC. (1991) p53 mutations in human cancers. Science 253:49-53.
65. Burns PA, Kemp CJ, Gannon JV, Lane DP, Bremmer R, Balmain A. (1991) Loss of heterozygosity and mutational alterations of the p53 gene in skin tumors of interspecific hybrid mice. Oncogene 6:2363-9.
66. El-Deiry WS, Harper JW, O'Connor PM, et al. (1994) WAFI/CIPI is induced in p53 mediated Gl arrest and apoptosis. Cancer Res. 54:1169-74.
67. Skvortsova I, Poper BA, Akvortsov S, et al. (2005) Pretreatment with Rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J. Radiation Res. 46:241-8.
68. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, El-Deiry WS. (2002) The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 1:47-55.
69. Bunz F, Hwang PM, Torrance C, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:263-9.